Does Pathologic Response Equate to Clinical Response Following SABR for Early-Stage NSCLC?

Does Pathologic Response Equate to Clinical Response Following SABR for Early-Stage NSCLC?

Bibliographic Details
Main Authors:	Eric D. Brooks, Vivek Verma, Joe Y. Chang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-06-01
Series:	Frontiers in Oncology
Subjects:	missile lung cancer NSCLC SBRT pathologic complete response PCR
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2019.00551/full

Similar Items

Prognostic Factors and Long-Term Survival in Locally Advanced NSCLC with Pathological Complete Response after Surgical Resection Following Neoadjuvant Therapy
by: Filippo Lococo, et al.
Published: (2020-11-01)

Surgical Resection Versus Stereotactic Body Radiation Therapy for Stage I NSCLC: Can Randomized Trials Provide the Solution?
by: Melanie P. Subramanian, et al.
Published: (2018-09-01)

Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation
by: Michael C. Repka, et al.
Published: (2017-10-01)

Dosimetric comparison of different algorithms in stereotactic body radiation therapy (SBRT) plan for non-small cell lung cancer (NSCLC)
by: Zhang J, et al.
Published: (2019-08-01)

Case Report: Pathological Complete Response in a Brain-Metastatic Lung Squamous Cell Carcinoma Patient With Long-Term Benefit From Chemo-Immunotherapy
by: Chen Hu, et al.
Published: (2021-09-01)

Impact of tissue heterogeneity corrections in stereotactic body radiation therapy treatment plans for lung cancer
by: Herman Tania De, et al.
Published: (2010-01-01)

Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report
by: Yong Tang, et al.
Published: (2020-04-01)

Stereotactic ablative radiotherapy as single treatment for early stage non‐small cell lung cancer: A single institution analysis
by: Xiaoli Zheng, et al.
Published: (2021-03-01)

Survival in early lung cancer patients treated with high dose radiotherapy is independent of pathological confirmation
by: Franz Zehentmayr, et al.
Published: (2019-02-01)

Particle therapy for non-small cell lung tumors: where do we stand?A systematic review of the literature
by: Krista eWink, et al.
Published: (2014-10-01)

Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [18F]FDG PET and CT perfusion: a prospective exploratory clinical study
by: Dae-Myoung Yang, et al.
Published: (2021-01-01)

Clinical impact of removing respiratory motion during liver SABR
by: M. Gargett, et al.
Published: (2019-06-01)

Case Report: Pathologic Complete Response to Pembrolizumab in Combination With Neoadjuvant Chemotherapy in a Patient With Stage IIB Squamous Lung Cancer
by: Lin Zhang, et al.
Published: (2020-11-01)

Predictive factors of achievement pathological complete response at neoadjuvant chemotherapy of primary operable breast cancer
by: O A Pavlikova, et al.
Published: (2017-01-01)

Ship Anti Ballistic Missile Response (SABR)
by: Johnson, Allen P., et al.
Published: (2012)

A Principal Component of Quality-of-Life Measures Is Associated with Survival: Validation in a Prospective Cohort of Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy
by: Mark K. Farrugia, et al.
Published: (2021-09-01)

Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy
by: Hiroshi Shintani, et al.
Published: (2021-06-01)

Quantitative analysis of cell-free DNA by droplet digital PCR reveals the presence of EGFR mutations in non-malignant lung pathologies
by: Rajesh Venkataram, et al.
Published: (2021-05-01)

Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR)
by: Dhaliwal, I., et al.
Published: (2022)

Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis
by: Shirata Yuko, et al.
Published: (2012-10-01)

SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
by: Yu Chen, et al.
Published: (2020-07-01)

1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT
by: Albano D, et al.
Published: (2018-08-01)

Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages
by: Florian Janke, et al.
Published: (2020-04-01)

Pathological complete response of locally advanced colon cancer after preoperative radiotherapy: a case report and narrative review of the literature
by: Sho Sekiya, et al.
Published: (2018-06-01)

Survival outcomes of locally advanced gastric cancer cases with pathological complete response received neoadjuvant chemotherapy
by: Qing Hu, et al.
Published: (2021-06-01)

Construction of Nomograms for Predicting Pathological Complete Response and Tumor Shrinkage Size in Breast Cancer
by: Yan S, et al.
Published: (2020-09-01)

Pathologic Response Rates after Neoadjuvant Therapy for Sarcoma: A Single Institution Study
by: Crystal Seldon, et al.
Published: (2021-03-01)

Quality Assessment of Gallbladder Cancer Pathology Reports: A Dutch Nationwide Study
by: Tessa J. J. de Bitter, et al.
Published: (2021-06-01)

The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery
by: Mina M. G. Youssef, et al.
Published: (2021-02-01)

Sequential Whole Exome Sequencing Reveals Somatic Mutations Associated with Platinum Response in NSCLC
by: Guo AX, et al.
Published: (2020-07-01)

Targeted Therapies in Early Stage NSCLC: Hype or Hope?
by: Alex Friedlaender, et al.
Published: (2020-08-01)

Diagnostics for Targeted NSCLC Therapy
by: Verena Schildgen, et al.
Published: (2017-11-01)

Focal Prostate Stereotactic Body Radiation Therapy With Correlative Pathological and Radiographic-Based Treatment Planning
by: Elisha Fredman, et al.
Published: (2021-09-01)

Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy
by: Anna Weiss, et al.
Published: (2018-04-01)

Pathological complete response after afatinib treatment of stage IV oligometastatic adenocarcinoma of the lung: the role of pulmonary surgery
by: Ping-Chung Tsai, et al.
Published: (2019-11-01)

Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports
by: Matthew D. Tucker, et al.
Published: (2020-12-01)

Analysis of long-term oncological results of clinical versus pathological responses after neoadjuvant treatment in locally advanced rectal cancer
by: Mariana F. Coraglio, et al.
Published: (2020-11-01)

A Nomogram for Predicting Pathological Complete Response to Neoadjuvant Chemoradiotherapy Using Semiquantitative Parameters Derived From Sequential PET/CT in Locally Advanced Rectal Cancer
by: Dae Hee Pyo, et al.
Published: (2021-10-01)

Clinical factors of post-chemoradiotherapy as valuable indicators for pathological complete response in locally advanced rectal cancer
by: Jianhong Peng, et al.

MRI-PATHOLOGICAL PARALLELS WITH THE COMPLETE TUMOR RESPONSE TO NEOADJUVANT CHEMORADIATION TREATMENT OF RECTAL CANCER
by: T. P. Berezoskaya, et al.
Published: (2019-06-01)

Cannot write session to /tmp/vufind_sessions/sess_fah1dfb9jmk5an2081gsc7h7v2